CUV 0.58% $14.47 clinuvel pharmaceuticals limited

Revenue EXPLOSION Coming?, page-47

  1. 1,132 Posts.
    lightbulb Created with Sketch. 511
    “CUV have treated one stroke patient. It will take another five years for the trials and approval process. The realistic chances of success are only 5-10%.

    Wolgen has already said they will try to use the data from PASS and other sources to bolster an application for Prenumbra. After all it is afamelanotide. Five years seems outlandish, they are slated to finish the program in 2023, two years from now. And if it works, likely with a breakthrough designation.
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
(20min delay)
Last
$14.47
Change
-0.085(0.58%)
Mkt cap ! $725.1M
Open High Low Value Volume
$14.60 $14.60 $14.32 $359.6K 24.84K

Buyers (Bids)

No. Vol. Price($)
17 750 $14.46
 

Sellers (Offers)

Price($) Vol. No.
$14.47 71 6
View Market Depth
Last trade - 13.13pm 10/09/2024 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.